Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors.
Olinvacimab (TTAC-0001) is a human monoclonal antibody targeting VEGFR-2/KDR with anti-angiogenic activity that blocks tumor angiogenesis and may be used to study solid tumors.
Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.
Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Aβ) for the study of Alzheimer's disease.
Ripertamab (SCT-400) is a recombinant human-mouse chimeric monoclonal antibody targeting CD20 that is cytotoxic and can be used to study hematologic malignancies.
Romosozumab (AMG-785) is a humanized monoclonal antibody that binds and inhibits sclerostin, increasing bone formation and decreasing bone resorption.Romosozumab is used in the study of postmenopausal osteoporosis.
ASG-5ME is a drug-antibody coupling targeting SLC44A4 that shows anti-tumor activity in xenograft models and may be used to study pancreatic and gastric cancer.
